FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Thierry Conroy; Pascal Hammel; Mohamed Hebbar; Meher Ben Abdelghani; Alice C. Wei; Jean-Luc Raoul; Laurence Chone; Eric Francois; Pascal Artru; James Joseph Biagi; Florence Castan; Jean-Baptiste Bachet

doi:https://doi.org/10.1056/nejmoa1809775

doi.org/10.1056/nejmoa1809775

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

,

,

..., Jean-Baptiste Bachet

40

Volume: 379, Issue: 25, Pages: 2395 - 2406

Published: Dec 20, 2018

Abstract

Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy. We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitabine as adjuvant therapy in patients with resected pancreatic cancer.We randomly assigned 493 patients with resected pancreatic ductal adenocarcinoma to receive a...

Paper Fields

Paper Details

Title

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

DOI

doi.org/10.1056/nejmoa1809775

Published Date

Dec 20, 2018

Volume

379

Issue

25

Pages

2395 - 2406

Citation AnalysisPro

You’ll need to upgrade your plan to Pro

Looking to understand the true influence of a researcher’s work across journals & affiliations?

Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.

Learn more

Notes

History